Articles tagged with Drug Targets
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
Scientists at Queen's University Belfast have developed a computer-aided data tool that can predict novel sites of binding for potential drugs. The tool aims to improve treatment for a range of illnesses by increasing therapeutic efficacy and reducing side effects.
A recent Johns Hopkins Medicine-led study suggests that statin use is not beneficial for reducing COVID-19 mortality or severity. Instead, patients taking statins had an increased risk of developing a more severe form of the disease. The researchers found no significant impact on mortality rates.
Researchers developed a molecular agent that can target lung and other cancer cells for imaging and treatment, distinguishing between healthy and cancerous cells. The new approach uses a unique chemistry method to tune the reactivity of the molecule, avoiding off-target effects.
A new study identifies three functional subtypes of cancer-associated fibroblasts (CAF) in lung cancer, which correspond to patients' treatment responses. These subtypes have distinct biological functions and therapeutic implications, suggesting that CAFs could serve as a key to enhancing personalized treatment for lung cancer patients.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
A new AI tool pairs protein pathways with clinical side effects and patient comorbidities to suggest targeted Covid-19 treatments. The tool, MOATAI-VIR, predicts 24 out of 26 major clinical manifestations of Covid-19 and their underlying disease-protein-pathway relationships.
Researchers discovered a mechanism that could prove useful in treating heart failure with preserved ejection fraction (HFpEF), a common and hard-to-treat condition. The new approach reduces exposure to increased cardiac stiffness, which is associated with lower-filling pressures inside the heart chambers.
Researchers found that females rely more heavily on aldosterone to regulate blood pressure, whereas males primarily use angiotensin II. This discovery could lead to targeted treatments for female hypertensive patients, improving treatment outcomes and reducing the risk of heart disease and stroke.
Researchers discovered that RSV's NS1 protein alters immune gene expression to evade the immune response. The study provides crucial data for targeting NS1 in drug or vaccine development and may shed light on the link between RSV and asthma.
Researchers from The Stuber Lab discovered that certain neurons in the brain light up in obese mice, preventing signals that indicate satiety. The study found that these neurons communicate with regions involved in depression and motivation, suggesting a link between eating disorders and addiction.
Researchers found that TAK1-inhibitors NG25 and 5Z-7 reduce the viability of multiple myeloma cell lines and primary cells, inducing apoptosis through various mechanisms. The combination of TAK1 inhibitors with DNA-damaging agents increases cytotoxicity in a synergistic or additive manner.
Researchers discovered that bumetanide, a 30-year-old diuretic, reverses signs of Alzheimer's disease in mice and human brain cells. The study also found that people over 65 who took bumetanide were less likely to develop Alzheimer's disease.
A recent study suggests that targeting alpha-synuclein protein in Parkinson's disease may not be sufficient to cure most patients. Instead, resolving brain inflammation caused by dysfunctional interferon-beta receptor signaling may hold the key to developing more effective treatments.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
Researchers at Trinity College Dublin have discovered that lactate can influence cells in the lung environment to support immune defenses against infection while limiting collateral damage. Lactate may hold therapeutic potential as a host-directed therapy for diseases like TB and COVID-19, which cause destruction of pulmonary tissue.
Dr. Gack's research focuses on identifying broad-spectrum antiviral drug targets and has implications for developing effective treatments against COVID-19 and other viral threats. The $5.6 million NIH grant will support her investigation into targeting human enzymes essential for virus replication.
Researchers found that a cancer chemotherapy drug can restore memory and cognitive function in mice with Alzheimer’s disease by inhibiting blood vessel growth. The study suggests repurposing approved anti-cancer drugs as treatments for Alzheimer’s disease, potentially shortening clinical development time.
Researchers have discovered toxic DNA buildup in the eyes of patients with geographic atrophy, a devastating form of age-related macular degeneration. Common HIV drugs or safer alternatives, such as Kamuvudines, may block inflammation and protect against retinal cell death, offering new hope for treatment.
Pediatric transplant recipients have a more robust immune response to COVID-19 vaccines, achieving higher antibody levels after two doses compared to adult counterparts. This study suggests that the standard two-dose regimen may be safe and effective in pediatric transplant recipients.
A recent study published in Frontiers in Immunology found that opioids can control gut immune responses, reduce colonic inflammation, and even promote the growth of regulatory T cells. The findings suggest that KNT-127 could be a promising therapeutic option for inflammatory bowel disease.
Jochen Zimmer, a UVA professor, has been awarded $9 million by the HHMI to pursue his research on biopolymer transport across biological membranes. His work aims to develop new biomaterials for medicines, food, and energy, potentially combating diseases, hunger, and climate change.
A new study at Ohio State University's Comprehensive Cancer Center is using rapid autopsies to gather biological samples after death to better understand how cancer cells overcome different treatments. This approach has already led to novel findings about drug resistance mechanisms, including the recent approval of a targeted therapy f...
The study reveals vast differences in gene expression and cytokine response across different chemotherapy agents, shedding light on their mechanisms of efficacy and toxicity in colorectal cancer. The findings contribute to the understanding of molecular bases of response in CRC tumors exposed to these drugs.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
A new global study found that setting targets for treating diabetes patients with cholesterol or blood pressure medication can significantly improve cardiovascular outcomes. Achieving these targets could save up to 6% of healthy lifetime lost to diabetes over 10 years, mainly due to reduced cardiovascular conditions.
Researchers have developed an AI-powered platform that allows scientists to grow virtual tumors and optimize nanoparticle designs using artificial intelligence. The new EVONANO platform has the potential to improve targeted cancer treatments, enabling personalized therapies for individual patients.
Researchers find PADI4 and HIF-1 proteins work together to deliver oxygen and nutrients to tumors, allowing them to grow. The discovery provides new avenues for anti-cancer therapies targeting blood vessel development.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
Researchers at UC Berkeley found that tumors release chemicals compromising the blood-brain barrier, leading to inflammation and tissue wasting. Blocking these chemicals could extend life span and improve health for cancer patients, reducing the need for toxic drugs.
A Bristol-led research team has identified specific receptors for the neurotransmitter acetylcholine that re-route information flowing through memory circuits in the hippocampus. The discovery holds promise for developing new, safer treatments for conditions like Alzheimer's disease and schizophrenia.
Researchers at Tel Aviv University have created a system that enables the production of 'good' bacteria capable of eliminating 'bad' bacteria. This breakthrough technology uses a toxin injection system to target specific types and amounts of toxins, offering an alternative to antibiotics.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
A new analytics platform, RDCA-DAP, will be launched to accelerate rare disease treatment innovation by hosting and standardizing rare diseases data. The platform is expected to empower patients and families to drive innovation in the field.
Despite its promise, cancer immunotherapy faces several hurdles, including limited efficacy and variable outcomes. Researchers are exploring new therapeutic targets and combination strategies to overcome resistance and improve patient outcomes.
A team of MIT engineers has developed a drug delivery capsule that can inject large quantities of monoclonal antibodies and other proteins into the stomach lining after being swallowed. The capsule overcomes a major challenge in delivering these drugs orally, which are usually administered via injections.
Scientists at Kyoto University developed a chemical compound that can tag and remove mutant DNA sequences from mitochondria, potentially treating mitochondrial diseases. The approach overcomes existing problems with genetic material injection and antioxidant drugs.
A genetic analysis of humans and rhesus macaques identified the NPSR1 gene as a risk factor for endometriosis. The study found that rare variants in this gene are associated with stage III/IV disease, leading to potential nonhormonal treatment targets for improved therapy.
A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.
Researchers reverse lung fibrosis in a mouse model using Bcl-2 inhibitor ABT-199, suggesting a novel therapeutic target to treat idiopathic pulmonary fibrosis. The study finds that monocyte-derived macrophages play a key role in fibrosis progression and that targeting the Cpt1a-Bcl-2 interaction modulates apoptosis resistance.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
Researchers have determined the structure of human leukotriene B4 receptor 1 (hBLT1), a protein involved in inflammation and disease. The analysis reveals how the receptor recognizes its binding partners and interacts with them, opening up avenues for designing better drugs.
The article considers the ethical issues surrounding enrolling children with neurodevelopmental conditions, such as autism spectrum disorder and fragile X syndrome, in clinical trials. Parents may face difficult decisions about whether to enroll their children due to concerns about potential loss of positive aspects of their condition.
Despite guidelines and legal requirements, women remain underrepresented in cardiovascular clinical trials, limiting treatment data on cardiovascular disease. Research shows that women respond differently to drugs than men, highlighting the need for sex-specific data in optimal care.
Researchers have identified a promising therapeutic target, METTL1, to treat aggressive cancers by inhibiting an RNA-modifying protein. The study found that targeting METTL1 effectively destroys cancer cells in laboratory models and mice while leaving healthy cells unharmed.
Researchers at Johns Hopkins Medicine have discovered that mebendazole, an anti-parasitic drug, can prevent and slow the growth of pancreatic cancer in genetically engineered mice. The study suggests that mebendazole may act similarly to collapsing cancer cells' structure and reducing inflammation.
A new technique called HT-MEK enables the simultaneous performance of thousands of enzyme experiments, allowing scientists to deeply probe into enzyme functions and structure. This could reveal clues about how enzymes work together to achieve their remarkable reactivity, enabling researchers to 'do enzymatic tricks' themselves.
A large-scale genetic study has identified new drug targets to treat type 1 diabetes by examining 61,427 participants and pinpointing 78 regions on the chromosomes that influence risk. The researchers found 36 previously unknown regions and specific gene variations that can be used to identify potential drug targets.
Researchers have developed a new type of nanocarrier that combines photothermal, chemo-therapy, and chemodynamic therapy to target and destroy cancer cells. The nanoclusters, which are responsive to near-infrared light, show a significant inhibitory effect on mouse tumor growth in vivo experiments.
Researchers at St. Jude Children's Research Hospital identified a metabolic control pathway that regulates T follicular helper cells, offering targets for drugs to stimulate the adaptive immune response and treat autoimmune diseases such as lupus. The finding holds promise for developing new vaccines and treatments.
A study at ECCMID identifies existing drugs that could be repurposed to treat gonorrhoea by targeting efflux pumps, which remove toxic compounds from bacterial cells. The research found 57 potential drug candidates, including dequalinium and doxorubicin, which may serve as lead compounds for new gonorrhea treatments.
A new study reveals 200 previously approved drugs that could be repurposed to treat COVID-19, with 40 already undergoing clinical trials. The research identified key proteins targeted by these drugs and found potential antiviral compounds, including proguanil and sulfasalazine.
Researchers at the University of Cambridge have identified 200 approved drugs that could be effective against COVID-19, including 160 previously unlinked to the infection. The study used computational biology and machine learning to create a comprehensive map of proteins involved in SARS-CoV-2 infection.
A novel drug candidate, KNT-127, has been developed to target glutamate-induced neurotransmission and reduce anxiety-like behavior in mice. The study proposes a new mechanism of action for treating anxiety disorder, which could lead to the development of evidence-based antipsychotics with a new mechanism.
The national tender system in Norway has significantly reduced the cost of biologic and targeted drugs for rheumatoid arthritis patients. Over a 10-year period, the average annual costs were lowered by approximately 50%, with current users experiencing a 50% reduction and new patients seeing a 75% decrease.
A study found that baseline use of biologic medications like rituximab and JAK inhibitors is associated with worse COVID-19 outcomes in people with rheumatoid arthritis. This association was seen even after adjusting for potential confounding factors.